En undersøgelse til evaluering af effektiviteten af remibrutinib sammenlignet med dupilumab på tidlige tidspunkter hos voksne med kronisk spontan urticaria utilstrækkeligt kontrolleret af anden generation H1-Antihistamines (RECLAIM)
En amerikansk fase 3b, multicenter, randomiseret, dobbeltblind, dobbelt-dummy-undersøgelse for at evaluere effektiviteten af remibrutinib sammenlignet med dupilumab på tidlige tidspunkter hos voksne med kronisk spontan urticaria utilstrækkeligt kontrolleret af anden generation H1-antihistaminer
This is a US, multi-center, randomized, double-blind, double-dummy, Phase 3b study to evaluate efficacy of remibrutinib (25 mg twice daily [b.i.d.] by mouth [p.o.]) compared to dupilumab (600 mg loading dose administered subcutaneously (s.c.) followed by 300 mg every 2 weeks s.c.) at early timepoints (4 weeks and earlier), when administered as an add-on treatment to second generation H1-antihistamines (sgH1-AH) (standard label dose as background therapy) in adult US participants with moderate to severe chronic spontaneous urticaria (CSU) inadequately controlled by sgH1-AHs.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
This study consists of a screening period (up to 4 weeks), a core treatment period (12 weeks double-blind, double-dummy), an optional open-label extension [OLE] period, and safety follow-up period.
Screening period: participants will have a screening period of a minimum of 7 days up to a maximum of 28 days to establish eligibility for the study. Participants meeting all the inclusion criteria and none of the exclusion criteria will be eligible to participate in the study.
Core treatment period (double-blind, double-dummy): approximately, 400 participants diagnosed with CSU inadequately controlled by sgH1-AH will be randomized in this study. Participants will be stratified based on prior exposure to anti-IgE biologics.
Eligible participants will be randomized in a 1:1 ratio to receive remibrutinib and placebo solution for injection or dupilumab and remibrutinib matching placebo, both as an add-on treatment to once daily standard label dose of sgH1-AH background therapy, until the Week 12 visit.
Additionally, all participants will be on a stable, standard label dose of a sgH1-AH ("background therapy") throughout the entire core treatment period (starting a minimum of 7 days prior to randomization until the end of Week 12). To treat unbearable symptoms of CSU, participants will be allowed to add more of the same sgH1-AH on an as-needed basis ("rescue therapy"). The total maximum daily dose of sgH1-AH (background plus rescue) should not exceed 4 tablets/day (4-fold the standard label dose).
Optional open-label extension [OLE] period: At the end of the 12-week double-blind treatment period, and in case remibrutinib is not commercially available, participants from both arms will be given the choice to roll over into an optional OLE safety period and receive remibrutinib (25 mg b.i.d. p.o.) for 12 weeks (up to Week 24).
Safety follow-up period:
- For participants who do not enter the OLE period: there will be a safety follow-up for 12 weeks with safety follow-up phone calls at Week 16 and Week 24 (Week 24 will be end of study).
- For participants who enter the OLE period: there will be 2 options at the end of Week 24:
- If remibrutinib is commercially available: participants will discontinue study treatment, perform their EOT visit and receive a safety follow-up phone call 4 weeks after the last dose of remibrutinib (this will be the EOS).
- If remibrutinib is not commercially available, participants may continue on remibrutinib 25 mg b.i.d. until its commercial availability and return for site visits for safety follow up and treatment dispensation every 3 months. When remibrutinib becomes commercially available, the participant will be contacted for a site visit to complete the EOT visit and will receive a safety follow-up phone call 4 weeks after the last dose of remibrutinib (this will be the EOS).
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35209
- Allervie Clinical Research
-
Birmingham, Alabama, Forenede Stater, 35244
- Cahaba Derm and skin hlth ctr 27
-
-
Arizona
-
Litchfield Park, Arizona, Forenede Stater, 85340
- Research Solutions of Arizona
-
Payson, Arizona, Forenede Stater, 85541
- Peak Dermatology
-
Phoenix, Arizona, Forenede Stater, 85032
- Premier Allergy Asthma And Immunology
-
Scottsdale, Arizona, Forenede Stater, 85254
- Orso Health
-
-
Arkansas
-
Little Rock, Arkansas, Forenede Stater, 72205
- Acuro Research Inc
-
-
California
-
Fountain Valley, California, Forenede Stater, 92708
- First OC Dermatology
-
Fremont, California, Forenede Stater, 95438
- Ctr for Dermatology Clinical Res
-
Huntington Beach, California, Forenede Stater, 92647
- Allergy and Asthma Specialists Group
-
Long Beach, California, Forenede Stater, 90808
- Orso Health
-
Long Beach, California, Forenede Stater, 90815
- Ark Clinical Research
-
Los Angeles, California, Forenede Stater, 90045
- Dermatology Research Associates
-
Los Angeles, California, Forenede Stater, 90025
- California Allergy and Asthma Medical Group
-
Napa, California, Forenede Stater, 94558
- One Of A Kind Clinical Research
-
Palo Alto, California, Forenede Stater, 94304
- Stanford University Medical Center
-
Pomona, California, Forenede Stater, 91767
- Empire Clinical Research
-
Redwood City, California, Forenede Stater, 94063
- Allergy and Asthma Consultants
-
Rocklin, California, Forenede Stater, 95765
- Norcal Clinical Research
-
Rolling Hills Estates, California, Forenede Stater, 90274
- Peninsula Research Associates
-
Sacramento, California, Forenede Stater, 95815
- Integrative Skin Science and Res
-
Sacramento, California, Forenede Stater, 95817
- UC Davis Neuromuscular Research Center
-
San Diego, California, Forenede Stater, 92123
- Therapeutics Clinical Research
-
Santa Monica, California, Forenede Stater, 90403
- Dermatology Institute and Skin Care
-
Upland, California, Forenede Stater, 91786
- Integrated Research of Inland Inc
-
Walnut Creek, California, Forenede Stater, 94598
- Allergy and Asthma Clin Res Inc
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80045
- University of Colorado Hospital - Aurora
-
Colorado Springs, Colorado, Forenede Stater, 80909
- Colorado ENT and Allergy
-
Colorado Springs, Colorado, Forenede Stater, 80907
- Asthma and Allergy Associates P C
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forenede Stater, 20059
- Howard University Hospital Division of Geriatrics
-
-
Florida
-
Aventura, Florida, Forenede Stater, 33180
- Florida Ctr Allergy Asthma Research
-
Boca Raton, Florida, Forenede Stater, 33486
- Skin Care Research Inc
-
Doral, Florida, Forenede Stater, 33172
- Omnicure Clinical Research
-
Fort Lauderdale, Florida, Forenede Stater, 33308
- FXM Clinical Research Ft Laud
-
Hollywood, Florida, Forenede Stater, 33021
- Skin Care Research LLC
-
Jacksonville, Florida, Forenede Stater, 32216
- Jacksonville Center for Clinical Research
-
Miami, Florida, Forenede Stater, 33176
- Miami Dade Medical Research
-
Miami, Florida, Forenede Stater, 33125
- University of MiamiHealth System
-
Miami, Florida, Forenede Stater, 33175
- FXM Clinical Res Miami LLC
-
Miramar, Florida, Forenede Stater, 33027
- Eminat LLC
-
North Miami Beach, Florida, Forenede Stater, 33162
- Ziaderm Research LLC
-
Panama, Florida, Forenede Stater, 32405
- AllerVie Health
-
Sarasota, Florida, Forenede Stater, 34233
- Sarasota Clinical Research
-
Sweetwater, Florida, Forenede Stater, 33172
- Lenus Research and Med Group LLC
-
Tampa, Florida, Forenede Stater, 33613
- Asthma Allergy Immunology Clin Res
-
Winter Park, Florida, Forenede Stater, 32789
- Conquest Research
-
-
Georgia
-
Columbus, Georgia, Forenede Stater, 31904
- AllerVie Clin Res Columbus GA
-
Cumming, Georgia, Forenede Stater, 30040
- Cleaver Medical Group
-
Douglasville, Georgia, Forenede Stater, 30135
- Southeast Dermatology Specialists
-
Savannah, Georgia, Forenede Stater, 31406
- Aeroallergy Research Laboratories
-
-
Idaho
-
Meridian, Idaho, Forenede Stater, 83642
- The Allergy Group-Meridian Clinic
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60612
- Rush University Medical Center
-
Chicago, Illinois, Forenede Stater, 60611
- NW Uni C and T Sciences Ins
-
Normal, Illinois, Forenede Stater, 61761
- Midwest Allergy Sinus Asthma SC
-
O'Fallon, Illinois, Forenede Stater, 62269
- Clinical Res Ctr of S Illinois
-
River Forest, Illinois, Forenede Stater, 60305
- Asthma and Allergy Center of Chicago S C
-
Skokie, Illinois, Forenede Stater, 60077
- Endeavor Health Clinical Trials Center
-
Wheaton, Illinois, Forenede Stater, 60189
- Accellacare Duly Health and Care
-
-
Indiana
-
Evansville, Indiana, Forenede Stater, 47715
- Deaconess Clin Allerg Res Inst
-
New Albany, Indiana, Forenede Stater, 47150
- Southern IN Clinical Trials
-
-
Iowa
-
Ames, Iowa, Forenede Stater, 50010
- McFarland Clinic PC
-
-
Kentucky
-
Bowling Green, Kentucky, Forenede Stater, 42104
- Equity Medical LLC
-
Louisville, Kentucky, Forenede Stater, 40215
- Family Allergy And Asthma Rsch Inst
-
Owensboro, Kentucky, Forenede Stater, 42301
- Allergy and Asthma Specialist P S C
-
-
Louisiana
-
Baton Rouge, Louisiana, Forenede Stater, 70816
- Ochsner Health Center
-
Lafayette, Louisiana, Forenede Stater, 70508
- Velocity Clinical Research
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21236
- Chesapeake Clinical Research Inc
-
Baltimore, Maryland, Forenede Stater, 21205
- Johns Hopkins U School of Med
-
Chevy Chase, Maryland, Forenede Stater, 20815
- Institute for Asthma and Allergy PC
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02111
- Boston Specialists LLC
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48106-0525
- ClinSite Inc
-
Caledonia, Michigan, Forenede Stater, 49316
- Derm Institute West Michigan PLLC
-
Detroit, Michigan, Forenede Stater, 48202
- Henry Ford Hospital
-
Troy, Michigan, Forenede Stater, 48084
- Somerset Skin Centre
-
Troy, Michigan, Forenede Stater, 48084
- Revival Research Institute
-
-
Minnesota
-
Minneapolis, Minnesota, Forenede Stater, 55455
- University of Minnesota
-
Minneapolis, Minnesota, Forenede Stater, 55402
- Clinical Research Institute
-
Rochester, Minnesota, Forenede Stater, 55905
- Mayo Clinic - Rochester
-
-
Missouri
-
Columbia, Missouri, Forenede Stater, 65201
- ENT and Allergy Center of Missouri
-
St Louis, Missouri, Forenede Stater, 63141
- The Clinical Research Center
-
St Louis, Missouri, Forenede Stater, 63141
- Washington University
-
-
Nebraska
-
Lincoln, Nebraska, Forenede Stater, 68510
- Somnos Clinical Research
-
-
Nevada
-
Las Vegas, Nevada, Forenede Stater, 89144
- Las Vegas Dermatology
-
Las Vegas, Nevada, Forenede Stater, 89128
- Allergy and Asthma Center of Las Vegas
-
-
New Jersey
-
Hamilton, New Jersey, Forenede Stater, 08619
- Circuit Clinical Mercer Algy Pulm
-
Little Silver, New Jersey, Forenede Stater, 07739
- Allergy Asthma Assoc Monmouth
-
Ocean Township, New Jersey, Forenede Stater, 07712
- Allergy Partners of New Jersey PC
-
-
New York
-
The Bronx, New York, Forenede Stater, 10467
- Montefiore Medical Center
-
The Bronx, New York, Forenede Stater, 10455
- Equity Medical
-
-
North Carolina
-
Asheville, North Carolina, Forenede Stater, 28801
- Allergy Partners Of West NC
-
Chapel Hill, North Carolina, Forenede Stater, 27516
- UNC DermatologyandSkinCancer Ctr
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater, 45231
- Bernstein Clinical Research Center
-
Columbus, Ohio, Forenede Stater, 43213
- CR Services Acquisition US
-
Fairborn, Ohio, Forenede Stater, 45324
- Wright State University
-
Toledo, Ohio, Forenede Stater, 43617
- Toledo Institute of Clinical Research
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forenede Stater, 73118
- Unity Clinical Research
-
Tulsa, Oklahoma, Forenede Stater, 74136
- Vital Prospects Clinical Research Institute
-
-
Oregon
-
Portland, Oregon, Forenede Stater, 97239
- Oregon Health Sciences University
-
Portland, Oregon, Forenede Stater, 97223
- Oregon Medical Research Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forenede Stater, 15213
- University of Pittsburgh Medical Center
-
Pittsburgh, Pennsylvania, Forenede Stater, 15241
- Allergy and Clinical Immunology Associates
-
-
South Carolina
-
Greenville, South Carolina, Forenede Stater, 29607
- Allergic Disease and Asthma Center
-
Greenville, South Carolina, Forenede Stater, 29601
- Tribe Clinical Research LLC
-
North Charleston, South Carolina, Forenede Stater, 29420
- National Allergy and Asthma Research LLS
-
North Charleston, South Carolina, Forenede Stater, 29406
- Charleston ENT and Allergy
-
-
Tennessee
-
Goodlettsville, Tennessee, Forenede Stater, 37072-2301
- Goodlettsville Dermatology Research
-
Murfreesboro, Tennessee, Forenede Stater, 37130
- International Clinical Research Tennessee LCC
-
-
Texas
-
Arlington, Texas, Forenede Stater, 76011
- Arlington Center for Dermatology
-
Austin, Texas, Forenede Stater, 78759
- Orion Clinical Research
-
Bellaire, Texas, Forenede Stater, 77401
- Bellaire Dermatology Associates
-
Dallas, Texas, Forenede Stater, 75230
- Reveal Research Institute
-
Dallas, Texas, Forenede Stater, 75231
- Pharma Research and Amp Consult
-
El Paso, Texas, Forenede Stater, 79924
- Western Sky Medical Research
-
Houston, Texas, Forenede Stater, 77030
- Center for Clinical Studies
-
Kerrville, Texas, Forenede Stater, 78028
- Sante Clinical Research
-
San Antonio, Texas, Forenede Stater, 78229
- Andante Research
-
San Antonio, Texas, Forenede Stater, 78213
- RFSA Dermatology
-
-
Utah
-
Murray, Utah, Forenede Stater, 84107
- University Of Utah
-
Sandy City, Utah, Forenede Stater, 84093
- Allergy Associates of Utah
-
-
Virginia
-
Vienna, Virginia, Forenede Stater, 22182
- Forefront Dermatology
-
-
Washington
-
Bellingham, Washington, Forenede Stater, 98225
- Bellingham Asthma Allergy and Immunology
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Adults ≥ 18 years of age at the time of signing the informed consent
- CSU duration for ≥ 6 months prior to screening (defined as the onset of CSU determined by the Investigator based on all available supporting documentation)
- Diagnosis of CSU inadequately controlled by sgH1-AH at the time of randomization, defined as:
- The presence of itch and hives for ≥ 6 consecutive weeks prior to screening despite the use of sgH1-AH during the 7 days prior to randomization (Day 1):
- UAS7 score (range, 0-42) ≥ 16, and
- ISS7 score (range, 0-21) ≥ 6, and
- HSS7 score (range, 0-21) ≥ 6
- Documentation of hives within 3 months before randomization (either at screening and/or at randomization); or documented in the participants medical history
- Willing and able to complete an Urticaria Patient Daily Diary (UPDD) for the duration of the study and adhere to the study protocol
- Participants must not have had more than one missing UPDD entry (either morning or evening) in the 7 days prior to randomization (Day 1)
Exclusion Criteria:
- Previous use of remibrutinib or other bruton's tyrosine kinase (BTK) inhibitors
- Previous use of dupilumab
- Evidence of clinically significant cardiovascular (such as but not limited to myocardial infarction, unstable ischemic heart disease, NYHA Class III/IV left ventricular failure, arrhythmia and uncontrolled hypertension within 12 months prior to Visit 1), neurological, psychiatric, pulmonary, renal, hepatic (past history or current), endocrine or metabolic disorder, or immunodeficiency that, in the investigator's opinion, would compromise the safety of the participant, interfere with the interpretation of the study results or otherwise preclude participation or protocol adherence of the participant.
- Evidence of hematological disorders (including coagulation disorders or significant bleeding risk)
- History or evidence of gastrointestinal disease (including gastrointestinal bleeding, e.g., in association with use of nonsteroidal anti-inflammatory drugs (NSAID), that was clinically relevant (e.g., where intervention was indicated or requiring hospitalization or blood transfusion)
- Requirement for anti-platelet medication, except for acetylsalicylic acid up to 100 mg/d or clopidogrel up to 75 mg/d. The use of dual anti-platelet therapy (e.g., acetylsalicylic acid + clopidogrel) is prohibited.
- Requirement for anticoagulant medication (for example, warfarin or Novel Oral Anti-Coagulants [NOAC])
- History or current hepatic disease including but not limited to acute or chronic hepatitis, cirrhosis or hepatic failure or hepatic parameters at screening: Aspartate Aminotransferase (AST)/ Alanine Aminotransferase (ALT) levels more than 1.5x ULN or International Normalized Ratio (INR) > 1.5 at screening
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Tredobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Treatment group 1: Remibrutinib + Placebo
Remibrutinib tablet (25 mg b.i.d. p.o.) + placebo solution for injection in pre-filled syringe (2 s.c. injections at baseline and then 1 s.c. injection every other week [Weeks 2-10]) |
Film-coated tablet, oral administration, 25 mg b.i.d. Solution for injection in pre-filled syringe every 2 weeks |
|
Aktiv komparator: Treatment group 2: Dupilumab + remibrutinib matching placebo
Dupilumab pre-filled syringe (600 mg loading dose [2 x 300 mg dupilumab s.c. injection] at baseline visit followed by dupilumab 300 mg s.c. injection every other week [Weeks 2-10]) + remibrutinib matching placebo tablet (1 tablet b.i.d. p.o.) |
Film-coated tablet, oral administration, b.i.d. Solution for injection in pre-filled syringe 600 mg loading dose followed by 300 mg dose every 2 weeks |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Absolute change from baseline in Weekly Urticaria Activity Score (UAS7) at Week 4
Tidsramme: Baseline, Week 4
|
The UAS7 is the sum of the Weekly Hives Severity (HSS7) score and the Weekly Itch Severity (ISS7) score, and ranges from 0-42. Weekly scores (HSS7 and ISS7 scores) will be derived by adding up the average daily scores of the 7 days preceding the visit. |
Baseline, Week 4
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Improvement of severity of hives, assessed as absolute change from baseline in HSS7 score at Week 4
Tidsramme: Baseline, Week 4
|
The hives (wheals) severity score, defined by number of hives, will be recorded by the participant twice daily in their eCOA device, on a scale of 0 (none) to 3. A weekly score (HSS7) is derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score is therefore 0 - 21. |
Baseline, Week 4
|
|
Improvement of severity of itch, assessed as absolute change from baseline in ISS7 score at Week 4
Tidsramme: Baseline, Week 4
|
The severity of the itch will be recorded by the participant twice daily in their eCOA device, on a scale of 0 (none) to 3 (severe). A weekly score (ISS7) is derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score is therefore 0 - 21. |
Baseline, Week 4
|
|
Improvement of UAS7, assessed as absolute change from baseline in UAS7 score at Week 1
Tidsramme: Baseline, Week 1
|
The UAS7 is the sum of the Weekly Hives Severity (HSS7) score and the Weekly Itch Severity (ISS7) score, and ranges from 0-42. Weekly scores (HSS7 and ISS7 scores) will be derived by adding up the average daily scores of the 7 days preceding the visit. |
Baseline, Week 1
|
|
Percentage of participants with UAS7 ≤ 6 at Week 4
Tidsramme: Week 4
|
Percentage of participants who achieved UAS7 ≤ 6 at Week 4. The UAS7 is the sum of the Weekly Hives Severity (HSS7) score and the Weekly Itch Severity (ISS7) score, and ranges from 0-42. Weekly scores (HSS7 and ISS7 scores) will be derived by adding up the average daily scores of the 7 days preceding the visit. |
Week 4
|
|
Percentage of participants with UAS7=0 at Week 4
Tidsramme: Week 4
|
Percentage of participants who achieved UAS7 = 0 at Week 4. The UAS7 is the sum of the Weekly Hives Severity (HSS7) score and the Weekly Itch Severity (ISS7) score, and ranges from 0-42. Weekly scores (HSS7 and ISS7 scores) will be derived by adding up the average daily scores of the 7 days preceding the visit. |
Week 4
|
|
Percentage of participants with UAS7 ≤ 6 at Week 2
Tidsramme: Week 2
|
Percentage of participants who achieved UAS7 ≤ 6 at Week 2. The UAS7 is the sum of the Weekly Hives Severity (HSS7) score and the Weekly Itch Severity (ISS7) score, and ranges from 0-42. Weekly scores (HSS7 and ISS7 scores) will be derived by adding up the average daily scores of the 7 days preceding the visit. |
Week 2
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Patologiske processer
- Kronisk sygdom
- Sygdomsegenskaber
- Sygdomme i immunsystemet
- Overfølsomhed, Øjeblikkelig
- Overfølsomhed
- Hudsygdomme
- Nældefeber
- Hudsygdomme, vaskulære
- Patologiske tilstande, tegn og symptomer
- Hud- og bindevævssygdomme
- Kronisk nældefeber
- Terapeutik
- Lægemiddeladministrationsruter
- Lægemiddelterapi
- Injektioner
- Dupilumab
- Remibrutinib
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- CLOU064AUS02
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .